Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005619
Status:
COMPLETED
Last Update Posted:
2011-02-21
First Post:
2000-05-02
Brief Title:
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Detection of Hairy Cell Leukemia Minimal Residual Disease Detection by Flow Cytometry
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia
PURPOSE Diagnostic trial to determine the effectiveness of analyzing blood and bone marrow to detect residual disease in patients who have previously treated hairy cell leukemia
PURPOSE Diagnostic trial to determine the effectiveness of analyzing blood and bone marrow to detect residual disease in patients who have previously treated hairy cell leukemia
Detailed Description:
OBJECTIVES I Compare the sensitivity of flow cytometry immunohistochemistry and polymerase chain reaction in detecting minimal residual disease following therapy with cladribine in patients with hairy cell leukemia
OUTLINE Blood and bone marrow samples are obtained from patients at time of bone marrow biopsies to assess minimal residual disease using flow cytometry immunohistochemistry and polymerase chain reaction Patients are followed for 2 years or until disease relapse
PROJECTED ACCRUAL A total of 15 patients will be accrued for this study over 12-24 months
OUTLINE Blood and bone marrow samples are obtained from patients at time of bone marrow biopsies to assess minimal residual disease using flow cytometry immunohistochemistry and polymerase chain reaction Patients are followed for 2 years or until disease relapse
PROJECTED ACCRUAL A total of 15 patients will be accrued for this study over 12-24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1754 | None | None | None |
| NU-97Z3 | None | None | None |